Chiasma
Dedicated to addressing the everyday challenges associated with existing therapies for rare and serious chronic diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€300m (Public information from May 2021)
Share price
$3.76 CHMA
Company register number 513104026
Jerusalem Jerusalem District (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | <1m | 20.0m | 80.0m |
| % growth | - | - | - | - | - | 2100 % | 300 % |
| EBITDA | - | (23.6m) | (29.1m) | (33.6m) | (63.6m) | - | - |
| % EBITDA margin | - | - | - | - | (7000 %) | - | - |
| Profit | - | (23.6m) | (28.2m) | (32.7m) | (67.3m) | (71.8m) | (32.7m) |
| % profit margin | - | - | - | - | (7400 %) | (359 %) | (41 %) |
| EV / revenue | - | - | - | - | 117.0x | - | - |
| EV / EBITDA | - | -1.6x | -2.4x | -3.2x | -1.7x | - | - |
| R&D budget | 30.0m | - | - | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | Series A | |
$7.7m | Series B | ||
$44.0m | Series C | ||
| N/A | $2.8m | Debt | |
| N/A | $10.0m | Debt | |
$38.5m | Series D | ||
$70.0m | Series E | ||
| N/A | N/A | IPO | |
| N/A | $34.5m | Post IPO Equity | |
$330m Valuation: $330m 330.0x EV/LTM Revenues -4.7x EV/LTM EBITDA | Acquisition | ||
| Total Funding | €147m | ||
Related Content
Recent News about Chiasma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.